newsfilter
← Latest News
Business Wire·

Humanigen Announces Target Enrollment in Phase 2/3 ACTIV-5/BET-B Trial of Lenzilumab for the Treatment of COVID-19 has Been Achieved

Top-line data from ACTIV-5/BET-B expected to be announced late in the first quarter or early in the second quarter of 2022 ACTIV-5/BET-B results to be shared with regulatory authorities in the US, UK, and EU as part of the ongoing review process